https://www.selleckchem.com/products/tp-0903.html
Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B-cell non-Hodgkin-type lymphoma (B-NHL) to evaluate its tolerability, safety, pharmacokinetics, and preliminary antitumor activity. Tazemetostat was given orally at a single dose of 800mg on the first day and 800mg twice daily (BID total 1600mg/d) on follo
Like
Comment
Share
